| Dr Roy S Antelyes, MD | |
|
100 W California Blvd, Pasadena, CA 91105-3010 | |
| (626) 397-3445 | |
| (626) 397-5643 |
| Full Name | Dr Roy S Antelyes |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 47 Years |
| Location | 100 W California Blvd, Pasadena, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275648610 | NPI | - | NPPES |
| 00G377270 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | G37727 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Huntington Memorial Hospital | Pasadena, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hmh Emergency Medical Group, Inc. | 7911800826 | 44 |
| Exer Medical Corporation | 9032359534 | 230 |
News Archive
Are you facing an issue that's having an effect on your life? Do you wish you had a secure environment where you could share openly and get real-life solutions you can start applying immediately? Enter FOCUS 7, a new forum in metro Detroit where individuals can meet, participate and learn how to resolve specific issues with the help of an expert on that topic.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
Scientists at the Walter and Eliza Hall Institute have identified a way that chemotherapy causes platelet numbers to drop, answering in the process a decade-old question about the formation of platelets, tiny cells that allow blood to clot.
Today, faculty members at the University of Colorado School of Medicine at the Anschutz Medical Campus announced the Safety in Dementia website, the first comprehensive online resource to help caregivers navigate issues related to firearm access and dementia.
Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "Liquid Formulations for the Prevention and Treatment of Mucosal Diseases and Disorders."
› Verified 7 days ago
| Entity Name | Providence Facey Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710031588 PECOS PAC ID: 3173436276 Enrollment ID: O20031105000822 |
News Archive
Are you facing an issue that's having an effect on your life? Do you wish you had a secure environment where you could share openly and get real-life solutions you can start applying immediately? Enter FOCUS 7, a new forum in metro Detroit where individuals can meet, participate and learn how to resolve specific issues with the help of an expert on that topic.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
Scientists at the Walter and Eliza Hall Institute have identified a way that chemotherapy causes platelet numbers to drop, answering in the process a decade-old question about the formation of platelets, tiny cells that allow blood to clot.
Today, faculty members at the University of Colorado School of Medicine at the Anschutz Medical Campus announced the Safety in Dementia website, the first comprehensive online resource to help caregivers navigate issues related to firearm access and dementia.
Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "Liquid Formulations for the Prevention and Treatment of Mucosal Diseases and Disorders."
› Verified 7 days ago
| Entity Name | Hmh Emergency Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659383024 PECOS PAC ID: 7911800826 Enrollment ID: O20040128001215 |
News Archive
Are you facing an issue that's having an effect on your life? Do you wish you had a secure environment where you could share openly and get real-life solutions you can start applying immediately? Enter FOCUS 7, a new forum in metro Detroit where individuals can meet, participate and learn how to resolve specific issues with the help of an expert on that topic.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
Scientists at the Walter and Eliza Hall Institute have identified a way that chemotherapy causes platelet numbers to drop, answering in the process a decade-old question about the formation of platelets, tiny cells that allow blood to clot.
Today, faculty members at the University of Colorado School of Medicine at the Anschutz Medical Campus announced the Safety in Dementia website, the first comprehensive online resource to help caregivers navigate issues related to firearm access and dementia.
Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "Liquid Formulations for the Prevention and Treatment of Mucosal Diseases and Disorders."
› Verified 7 days ago
| Entity Name | Exer Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588901532 PECOS PAC ID: 9032359534 Enrollment ID: O20130705000153 |
News Archive
Are you facing an issue that's having an effect on your life? Do you wish you had a secure environment where you could share openly and get real-life solutions you can start applying immediately? Enter FOCUS 7, a new forum in metro Detroit where individuals can meet, participate and learn how to resolve specific issues with the help of an expert on that topic.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
Scientists at the Walter and Eliza Hall Institute have identified a way that chemotherapy causes platelet numbers to drop, answering in the process a decade-old question about the formation of platelets, tiny cells that allow blood to clot.
Today, faculty members at the University of Colorado School of Medicine at the Anschutz Medical Campus announced the Safety in Dementia website, the first comprehensive online resource to help caregivers navigate issues related to firearm access and dementia.
Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "Liquid Formulations for the Prevention and Treatment of Mucosal Diseases and Disorders."
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Roy S Antelyes, MD Po Box 60259, Los Angeles, CA 90060-0259 Ph: (626) 447-0296 | Dr Roy S Antelyes, MD 100 W California Blvd, Pasadena, CA 91105-3010 Ph: (626) 397-3445 |
News Archive
Are you facing an issue that's having an effect on your life? Do you wish you had a secure environment where you could share openly and get real-life solutions you can start applying immediately? Enter FOCUS 7, a new forum in metro Detroit where individuals can meet, participate and learn how to resolve specific issues with the help of an expert on that topic.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
Scientists at the Walter and Eliza Hall Institute have identified a way that chemotherapy causes platelet numbers to drop, answering in the process a decade-old question about the formation of platelets, tiny cells that allow blood to clot.
Today, faculty members at the University of Colorado School of Medicine at the Anschutz Medical Campus announced the Safety in Dementia website, the first comprehensive online resource to help caregivers navigate issues related to firearm access and dementia.
Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "Liquid Formulations for the Prevention and Treatment of Mucosal Diseases and Disorders."
› Verified 7 days ago
Dr. David Michael Ulick, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 W California Blvd, Department Of Emergency Medicine, Pasadena, CA 91109 Phone: 626-397-5106 | |
Dr. Nicholas Withrow Greco, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 W California Blvd, Pasadena, CA 91105 Phone: 626-397-5112 | |
Dr. Paul Chahn Rhee, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 W California Blvd, Pasadena, CA 91105 Phone: 626-397-3445 Fax: 626-397-5643 | |
Dr. Asbasia Aboelkhair Mikhail, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 W California Blvd, Pasadena, CA 91105 Phone: 626-397-3445 Fax: 626-397-5643 | |
Dr. Charles Walter Bugg, M.D., PH.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 W California Blvd, Pasadena, CA 91125 Phone: 626-397-5116 | |
Asa Kristian Scott, ATC Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2560 Lambert Dr, Pasadena, CA 91107 Phone: 626-616-2622 | |
Dr. Joanna Maack, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 W California Blvd, Pasadena, CA 91105 Phone: 917-929-7870 |